U.S. markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
7,786.00+154.00 (+2.02%)
At close: 4:45PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7,632.00
Bid7,782.00 x 0
Ask7,783.00 x 0
Day's Range7,642.00 - 7,808.70
52 Week Range71.46 - 10,120.00
Avg. Volume2,947,311
Market Cap102.211B
Beta (5Y Monthly)0.21
PE Ratio (TTM)36.30
EPS (TTM)214.50
Earnings DateJul 29, 2021
Forward Dividend & Yield2.07 (2.71%)
Ex-Dividend DateFeb 25, 2021
1y Target Est78.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg

      UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg

      The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc’s (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources quoted by Bloomberg. The rethink comes shortly before the first data from the treatment’s trials that are expected in the coming weeks. In the U.K., where two-thirds of the population have already received the first dose of a COVID-19 vaccine, the potential benefits of AZD7442 may no longer hold enough allure to convince the government to follow through on its agreement with AstraZeneca. AstraZeneca agreed to provide the U.K. with one million doses of its long-acting COVID-19 antibody AZD7442 in November. The deal announced last year was a non-binding and in-principle agreement. By contrast, the U.S. increased its order for AstraZeneca’s antibody treatment by half a million doses in March, taking its potential supplies to 700,000 in 2021. AstraZeneca has completed the dosing in Phase 2/3 trials of AZD7442 in prophylaxis and post-exposure prophylaxis settings. Data from the post-exposure prophylaxis study are due in the first half of 2021, with the results of the prophylaxis study set to follow before the end of 2021. AstraZeneca was still dosing in an outpatient treatment setting phase 2/3 study as of its latest update. The company has five advanced-stage trials testing a combination of two long-acting antibodies to prevent and treat COVID-19 in different populations. Price Action: AZN shares are trading 1.12% higher at $54.71 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaEuropean Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: ReutersFDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Reuters

      UPDATE 1-Swiss aim to re-open economy, donate AstraZeneca COVID-19 shots

      Switzerland aims to expand its economic re-opening and may donate millions of AstraZeneca COVID-19 vaccine doses to developing countries as the Alpine nation grows increasingly confident it is beating back the pandemic. Health Minister Alain Berset on Wednesday said the country may give 3 million of 5.4 million AstraZeneca doses it has reserved to the COVAX vaccine sharing programme. Switzerland has enough mRNA shots from producers including Pfizer and Moderna to cover 2021 and 2022, Berset said.